	US 11,873,349 B1
	Compositions and methods related to IL27 receptor binding
Robert Kastelein, Menlo Park, CA (US); Patrick Lupardus, Menlo Park, CA (US); and Deepti Rokkam, Menlo Park, CA (US)
Assigned to Synthekine, Inc., Menlo Park, CA (US)
Filed by Synthekine, Inc., Menlo Park, CA (US)
Filed on Feb. 3, 2023, as Appl. No. 18/164,386.
Application 18/164,386 is a continuation of application No. PCT/US2021/044577, filed on Aug. 4, 2021.
Claims priority of provisional application 63/135,884, filed on Jan. 11, 2021.
Claims priority of provisional application 63/078,745, filed on Sep. 15, 2020.
Claims priority of provisional application 63/061,562, filed on Aug. 5, 2020.
Int. Cl. C07K 16/46 (2006.01); C12N 15/63 (2006.01); A61P 37/02 (2006.01)

CPC C07K 16/468 (2013.01) [A61P 37/02 (2018.01); C12N 15/63 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01)]

6 Claims

1. An IL27 receptor (IL27R) binding protein that specifically binds to IL27Rα subunit (IL27Rα) and glycoprotein 130 subunit (gp130),

wherein the binding protein causes the multimerization of IL27Rα and gp130 when bound to IL27Rα and gp130, and

wherein the binding protein comprises a single-domain antibody (sdAb) that specifically binds to IL27Rα (an anti-IL27Rα sdAb) and a sdAb that specifically binds to gp130 (an anti-gp130 sdAb) and wherein the anti-IL27Rα sdAb is an anti-IL27Rα V_HH antibody and the anti-gp130 sdAb is an anti-gp130 V_HH antibody and

wherein the anti-gp130 V_HH antibody comprises a set of a CDR1, a CDR2, and a CDR3, wherein the set is selected from the group consisting of:

SEQ ID NO: 193, SEQ ID NO: 199, SEQ ID NO: 205, respectively;

SEQ ID NO: 194, SEQ ID NO: 200, SEQ ID NO: 206, respectively;

SEQ ID NO: 195, SEQ ID NO: 201, SEQ ID NO: 207, respectively;

SEQ ID NO: 196, SEQ ID NO: 202, SEQ ID NO: 208, respectively;

SEQ ID NO: 197, SEQ ID NO: 203, SEQ ID NO: 209, respectively; and

SEQ ID NO: 198, SEQ ID NO: 204, SEQ ID NO: 210, respectively; and

the anti-IL27Rα V_HH antibody comprises a set of a CDR1, a CDR2, and a CDR3, wherein the set is selected from the group consisting of

SEQ ID NO: 211, SEQ ID NO: 218, SEQ ID NO: 225, respectively;

SEQ ID NO: 212, SEQ ID NO: 219, SEQ ID NO: 226, respectively;

SEQ ID NO: 213, SEQ ID NO: 220, SEQ ID NO: 227, respectively;

SEQ ID NO: 214, SEQ ID NO: 221, SEQ ID NO: 228, respectively;

SEQ ID NO: 215, SEQ ID NO: 222, SEQ ID NO: 229, respectively;

SEQ ID NO: 216, SEQ ID NO: 223, SEQ ID NO: 230, respectively; and

SEQ ID NO: 217, SEQ ID NO: 224, SEQ ID NO: 231, respectively.